Clearside Biomedical, Inc. - CLSD STOCK NEWS

Clearside Biomedical (Nasdaq: CLSD) announced positive topline results from its partner Arctic Vision's Phase 3 clinical trial of ARCATUS® (ARVN001) for treating Uveitic Macular Edema (UME) in China. The trial met primary and secondary endpoints, showing significant visual acuity improvement and edema control. Key findings include:

- 38.5% of ARVN001-treated patients gained ≥15 ETDRS letters in vision vs 9.4% in the sham group
- Central subfield thickness reduction: 204.3 microns (ARVN001) vs 1.6 microns (sham)
- Mean BCVA gain: 9.6 letters at week 4, 12.2 letters at week 24
- No ocular serious adverse events reported

Additionally, Arctic Vision's new drug applications for ARCATUS have been accepted in Australia and Singapore, expanding the global opportunity for XIPERE®, Clearside's FDA-approved suprachoroidal space (SCS®) injection treatment.

Clearside Biomedical (Nasdaq: CLSD) has opened registration for a virtual key opinion leader (KOL) event on July 24, 2024, from 8:00 - 9:15 am ET. The webinar will focus on suprachoroidal drug delivery and its applications in retinal treatments, particularly for neovascular age-related macular degeneration (wet AMD). The event will feature presentations by renowned retinal experts:

1. Dr. David M. Brown, Director of Research at Retina Consultants Houston
2. Dr. Glenn C. Yiu, Professor of Ophthalmology at UC Davis
3. Dr. Victor Chong, Chief Medical Officer of Clearside Biomedical

The webinar will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, ongoing clinical programs, and potential future development opportunities for Clearside.

Clearside Biomedical (Nasdaq: CLSD), renowned for its innovative suprachoroidal space (SCS®) therapies, has appointed Dr. Glenn C. Yiu to its Scientific Advisory Board (SAB). Dr. Yiu, Professor of Ophthalmology at UC Davis, brings extensive expertise in retinal diseases, gene therapy, and ocular imaging. He has pioneered significant advances, including using CRISPR-based genome editing for age-related macular degeneration (AMD) and developing microneedles for gene delivery. His role is poised to enhance Clearside's CLS-AX program and pipeline expansion. Dr. Yiu's appointment underlines Clearside's commitment to advancing retinal disease treatments through cutting-edge research and innovation.

Clearside Biomedical (Nasdaq: CLSD) will host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024, from 8:00 to 9:15 am ET. The event will focus on the use and versatility of suprachoroidal drug delivery, especially in treating neovascular age-related macular degeneration (wet AMD).

Expert retinal specialists, including Dr. David M. Brown, Dr. Glenn C. Yiu, and Dr. Victor Chong, will share their real-world experiences and insights. The webinar will discuss the current and future applications of Clearside's suprachoroidal delivery platform, including potential pipeline expansion.

The webinar will conclude with a live Q&A session. The live and archived webcast can be accessed on Clearside's website under the Investors section.

Clearside Biomedical (Nasdaq: CLSD) showcased its leadership in suprachoroidal delivery at the Clinical Trials at the Summit (CTS) Meeting on June 8, 2024. The presentations highlighted the broad application of suprachoroidal injections in treating retinal diseases, noting the promising safety and efficacy of their SCS Microinjector®. Dr. Victor Chong emphasized the potential of their FDA-approved product and the forthcoming CLS-AX data for wet AMD. Key studies presented included real-world data on XIPERE®, displaying 75% durability over six months, and updates on the ongoing ODYSSEY trial for CLS-AX with topline data expected in Q3 2024. Partner organizations presented data on their investigational therapies using Clearside's delivery platform for various ophthalmic conditions.

Clearside Biomedical announced that the journal RETINA has published new consensus guidelines for drug delivery via suprachoroidal space (SCS) injection. These guidelines, co-authored by 16 retinal physicians, detail best practices for SCS injection, including patient preparation, injection techniques, and post-injection care. This publication supports the use of Clearside's SCS Microinjector, which is already FDA-approved for uveitic macular edema and used in six ongoing clinical trials for various retinal diseases. Clearside's President, George Lasezkay, and Chief Medical Officer, Victor Chong, emphasized the clinical acceptance and adoption of their delivery platform.

Clearside Biomedical, Inc. (Nasdaq: CLSD) reported Q1 2024 financial results, focusing on the Phase 2b ODYSSEY Trial in Wet AMD with data expected in Q3 2024. The company aims to revolutionize eye therapy delivery through the suprachoroidal space. Management team strengthened with key additions like new Chief Medical Officer and Board member. Revenue increased, highlighting the successful completion of a direct offering, and positive data presentations on suprachoroidal drug delivery.

Clearside Biomedical, Inc., a biopharmaceutical company specializing in delivering therapies to the back of the eye, will have its CEO and CMO participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on May 14, 2024. The webcast can be accessed on the company's website.

Clearside Biomedical, Inc., will report its first quarter 2024 financial results on May 9, 2024, after the market closes. The company will also provide a corporate update during a webcast and conference call. Investors can access the live and archived webcast on the Clearside website and join the call by dialing the provided numbers.